# KPV Peptide for Skin Repair and Barrier Protection | Research > KPV peptide skin repair research: keratinocyte signaling, corneal re-epithelialization (8/8 by 60 h), and fine-dust protection in cell models. Cited, research-only. The keratinocyte, corneal, and wound-repair literature on the alpha-MSH C-terminal tripeptide — what cell and animal studies measured, and where they stop. ## In plain English This page covers KPV peptide skin repair research — what studies of skin and eye-surface healing have found. In short: when researchers put KPV on rabbit eyes after injury, the surface healed faster (every treated eye fully healed by about two and a half days). In human skin cells, KPV calmed inflammation the same way the full hormone does, and a 2025 study found it shielded skin cells from damage caused by airborne dust. These are dish-and-animal results. The creams and dressings tested are research formulations, not approved skincare or medicine. KPV does not tan or pigment skin. ## Why KPV peptide skin repair research exists at all KPV is the C-terminal fragment of alpha-MSH, a hormone with a long-recognized role in skin biology — but the fragment is studied precisely because it splits the hormone's two jobs apart. KPV keeps the anti-inflammatory signaling and drops the pigmentary (melanogenic) action [4]. For skin and wound research, that is the appealing combination: calm inflammation and support repair without driving pigmentation [4][8]. In human keratinocyte (epidermal skin-cell) systems, alpha-MSH, the C-terminal MSH(11-13)/KPV fragment, and ACTH signaled through shared anti-inflammatory pathways, and the fragment reproduced the anti-inflammatory signaling of the full hormone in those cutaneous cells [7]. A review evaluating melanocortin peptides as candidate agents for cutaneous wound healing discusses KPV among peptides that may promote repair through anti-inflammatory and pro-repair actions [8]. ## Corneal re-epithelialization: the cleanest readout The most quantitatively precise skin-adjacent result is in the eye surface. Topical KPV (the alpha-MSH 11-13 fragment), dosed as 30 uL drops at 1, 5, or 10 mg/mL four times daily for four days, accelerated corneal epithelial wound healing in rabbits via a nitric-oxide-dependent mechanism [6]. By 60 hours, 8 of 8 corneas treated with KPV were completely re-epithelialized versus none of the placebo-treated corneas (P<0.05) [6]. In cultured rabbit corneal epithelial cells the active range was 0.1-10 uM [6]. The cornea is an epithelial surface, so the result is read as evidence of epithelial wound-closure support rather than a cosmetic claim [6]. ### Has KPV been studied for wound healing? Yes. Topical alpha-MSH(11-13)/KPV accelerated corneal epithelial wound healing in rabbits, with 8 of 8 corneas fully re-epithelialized by 60 hours versus none on placebo [6]. KPV also appears in cutaneous wound-repair and tripeptide regeneration reviews as a pro-repair, anti-inflammatory candidate [8][13]. These are animal and review findings, not human wound-care outcomes [6]. ## Barrier and environmental-stress protection in cell models A 2025 in vitro study reported that the Lysine-Proline-Valine peptide reduced fine-dust (particulate-matter)-induced keratinocyte apoptosis (programmed skin-cell death) and inflammatory signaling, supporting a protective role against environmental skin stress in cell models [9]. A 2025 comprehensive review of tripeptides in wound healing and skin regeneration includes KPV among agents that support repair via anti-inflammatory and pro-repair mechanisms [13]. Biomaterial delivery is part of the same research thread: a skin-adaptive film dressing with smart growth-factor release accelerated diabetic wound closure in a rodent model, contextualizing how anti-inflammatory peptides are paired with dressings for repair [15]. ### Can KPV help skin exposed to pollution or fine dust? A 2025 in vitro study found the Lysine-Proline-Valine peptide reduced fine-dust (particulate-matter)-induced keratinocyte apoptosis and inflammation, suggesting a protective role against environmental skin stress in cell models [9]. This is a cell-culture finding; it has not been tested in human skin [9]. ### What is KPV cream used for? In research, topical and biomaterial-delivered KPV has been studied in skin and wound-repair models — keratinocyte signaling, environmental skin stress, and mucoadhesive or film dressings [7][9][13]. These are research formulations, not approved cosmetic or medical creams [9]. No human cosmetic or therapeutic KPV cream is established [9]. ### Does KPV cause skin pigmentation or tanning like other melanocortins? No. KPV is the C-terminal alpha-MSH fragment that retains anti-inflammatory activity while lacking the parent hormone's pigmentary (melanogenic) action [4]. That loss of tanning effect is its defining feature in the literature and the reason it is studied separately from melanocortin agonists used in pigmentation research [4]. ## What this page is not The skin and wound-repair record for KPV is preclinical: cell cultures, rabbit cornea, and rodent biomaterial models, plus reviews [6][9][13]. There are no human trials, no validated human pharmacokinetics, and no approved cosmetic or medical KPV product [1][9]. The topical and oral KPV described above are research formulations, not approved cosmetic or medical creams [9]. Full mechanism and the gut literature are in our [KPV research findings](/research); regulatory standing is on [KPV legal status and 503A compounding access](/legal-status). --- A holographic readout of the published KPV tripeptide record — each gut, skin, and wound-repair finding logged to its primary source and tagged by evidence strength, the absent human trials and the FDA-evaluation standing left lit in plain sight; no clinic behind the console and nothing here dispensed or sold.